No Data
No Data
The construction of specialized traditional Chinese medicine departments is accelerating, and TCM clinical services maintain high prosperity.
Golden Owl Financial News | According to recent reports from CCTV News on the National Administration of Traditional Chinese Medicine, through a series of measures such as accelerating the construction of Traditional Chinese Medicine advantageous specialties, the high-quality development of county-level Traditional Chinese Medicine Hospitals, and the construction of collaborative hospitals for Chinese and Western medicine, China has now established 1,158 national advantageous specialties in Traditional Chinese Medicine. The next step will be to build a network of advantageous specialties in Traditional Chinese Medicine and create clusters of advantageous specialties, focusing on strengthening the construction of pediatrics, geriatrics, and mental illness specialties, as well as promoting the foundation and quality of county-level Traditional Chinese Medicine hospitals and enhancing grassroots Traditional Chinese Medicine service capabilities. Under the dual drive of policy and clinical demand, the Traditional
GTJA: The centralized procurement of Chinese Patent Medicine is still in the early stages, and quality improvement and expansion are expected to continue to progress.
GTJA released a Research Report stating that the bidding for the third batch of national Chinese Patent Medicine centralized procurement has opened, with the reduction slightly exceeding expectations.
The seasonal influenza A has entered the epidemic period, and the sales of related Chinese Patent Medicine products have significantly increased.
① Recently, the positive rate of influenza virus has significantly increased, with over 99% being type A influenza. Market data shows a clear increase in the demand for various Traditional Chinese Medicine cold medicine products. ② Today, stock prices of several listed companies in the Traditional Chinese Medicine Industry, such as Shanxi Zhendong Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Zhongsheng Pharmaceutical, have reached the daily limit, with the Traditional Chinese Medicine Sector overall rising, and the Traditional Chinese Medicine 50 ETF increasing by 3.21%.
Tong Ren Tang Technologies Renews Trademark Licence Contract With Tong Ren Tang Chinese Medicine
TONGRENTANGCM (03613.HK) has entered into a technical service contract with TONG REN TANG.
On December 20, Gelonghui reported that TONGRENTANGCM (03613.HK) announced that on December 20, 2024, the company entered into a technical service contract with TONG REN TANG. Accordingly, the company entrusted TONG REN TANG with the process and technical research on important Traditional Chinese Medicine raw materials. The company shall pay TONG REN TANG a total of 5 million Hong Kong dollars in installments for the technical services. The related raw materials are an important part of the group's production of Traditional Chinese Medicine and products, playing a significant role in the quality of the production process. Considering TONG REN TANG's capabilities and expertise in Traditional Chinese Medicine manufacturing, the Director believes that the technical service contract and the Trade involved will be beneficial.
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.